Not Signed In - La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent(R) Study
Tue, 07 Nov 2006 08:00 AM EST
... La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced significant progress in enrolling patients and opening sites for its Phase 3 clinical trial of Riquent(R) (abetimus sodium) for the treatment of lupus renal disease. To date, 82 patients have been enrolled in the study, with 40 patients randomized in October. [click link for full article] ...
Related Topics
- International Health
- Tolterodine
- Yoga
- Phenylephrine and Guaifenesin ER Tablets
- Guaifenesin and Potassium Guaiacolsulfonate
- Phenylephrine and Guaifenesin Capsules
- Psychopharmacology
- Smoking Cessation and Continued Risk in Cancer Patients
- Rue
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Pseudoephedrine and Guaifenesin ER
- Retinoblastoma
- Propranolol
- Peritoneal Dialysis
- Radiation Studies
- CHF
- Diltiazem ER
- International Classification of Diseases
- Pseudoephedrine and Guaifenesin
email this page
print this page
bookmark this page
feedback on this page
